- Nuvation Bio Announces Data from Pivotal Phase 2 TRUST-I Study of its Investigational ROS1 Inhibitor, Taletrectinib, are Published in the Journal of Clinical Oncology and Reported at 2024 ASCO Annual Meeting
- Nuvation Bio to Present at the Jefferies Global Healthcare Conference
- Nuvation Bio Reports First Quarter 2024 Financial Results and Provides Business Update
- Nuvation Bio to Present Updated Data on Taletrectinib, a ROS1 inhibitor, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
- Nuvation Bio Completes Acquisition of AnHeart Therapeutics
More ▼
Key statistics
On Friday, Nuvation Bio Inc (NUVB:NYQ) closed at 3.03, -27.16% below its 52-week high of 4.16, set on Mar 28, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.94 |
---|---|
High | 3.03 |
Low | 2.87 |
Bid | 2.96 |
Offer | 3.01 |
Previous close | 2.93 |
Average volume | 2.64m |
---|---|
Shares outstanding | 247.17m |
Free float | 179.19m |
P/E (TTM) | -- |
Market cap | 748.93m USD |
EPS (TTM) | -0.3146 USD |
Data delayed at least 15 minutes, as of Jul 06 2024 00:00 BST.
More ▼